HOME >> BIOLOGY >> NEWS
Brookhaven scientists determine key Lyme disease protein structure

UPTON, NY A research team working at the U.S. Department of Energys Brookhaven National Laboratory has determined the three-dimensional structure of a key protein on the bacterium that causes Lyme disease. Called OspC, the protein is derived from two strains of the Lyme disease bacterium. This research may lead to a second-generation vaccine that would be more effective than the current one.

The current vaccine is based on another Lyme disease protein, known as OspA, which was previously deciphered at Brookhaven. Both OspA and OspC are outer surface proteins of Borrelia burgdoferi, the bacterium that causes Lyme disease. Researchers from Brookhaven Lab, Stony Brook Universitys School of Medicine, the University of Rochester Medical Center and Rutgers University will report their findings on the structure of OspC in the March 1, 2001 edition of The EMBO Journal.

Spread by the bite of an infected deer tick, Lyme disease is the most common vector-borne disease in the U.S. Between 1982 and 1996, more than 99,000 cases were reported in the nation. Early symptoms of the disease include a bulls-eye rash and flu-like symptoms. If the disease is not promptly treated with antibiotics, more serious symptoms, including joint and neurological complications, may develop.

To determine the structure of OspC, the researchers used a technique at Brookhavens National Synchrotron Light Source (NSLS) known as multiple wavelength anomalous diffraction. First, researchers grew crystals of the protein that could withstand the intense x-rays at the NSLS. To make large quantities of OspC, the team used the T7 gene-expression system, which was developed at Brookhaven.

Then the crystal was illuminated with beams of x-rays at different energies, and diffraction patterns were recorded on a detector. With the aid of powerful computers, the researchers then analyzed the diffraction patterns to gain the vital information needed to create an image of the protein
'"/>

Contact: Diane Greenberg
greenb@bnl.gov
631-344-2347
DOE/Brookhaven National Laboratory
27-Feb-2001


Page: 1 2

Related biology news :

1. Brookhaven lab biophysicist F. William Studier wins R&D 100 award
2. Workshop for new synchrotron light source at Brookhaven
3. Brookhaven Lab expects $30 million to support life sciences
4. Brookhaven Lab develops ThraxVac to clean up anthrax
5. Brookhaven Lab & Battelle collaborate on research that may lead to novel anti-microbial drugs
6. Rice, Brookhaven physicists decode initial stage of cell fusion
7. Brookhaven Lab scientist wins Environmental Mutagen Society Award
8. Brookhaven Spotlights: News from the National Synchrotron Light Source
9. Enzyme studies at Brookhaven Lab may lead to new antiviral agents
10. New Brookhaven Lab study shows how ritalin works
11. New test for radiation damage to DNA developed at Brookhaven Lab

Post Your Comments:
(Date:10/31/2014)... in programmed cell death, offering new targets for the ... , The research teams from the Walter and ... structure of a key cell death protein called Bak ... cell death. Their studies were published in ... the National Academy of Sciences . , ...
(Date:10/30/2014)... or reverse soil subsidence and reduce greenhouse gas ... River Delta by Dartmouth College researchers and their ... the first to continually measure the fluctuations of ... wetlands, appears in the journal by ... drainage of organic soils has resulted in vast ...
(Date:10/30/2014)... therapeutics present unique challenges when it comes to ... harm. New consensus guidelines for toxicity testing that ... characteristics of these novel biopharmaceuticals are presented in ... from Mary Ann Liebert, Inc. publishers . ... Nucleic Acid Therapeutics website until November 30, ...
Breaking Biology News(10 mins):A matter of life and death: Cell death proteins key to fighting disease 2Dartmouth study finds restoring wetlands can lessen soil sinkage, greenhouse gas emissions 2New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2
(Date:10/30/2014)... October 30, 2014 Grace Century portfolio project, ... A. Manganello, Chairman of the Board, to the National ... The appointment was made by the Ministry of Health on ... 2014. , More than a year after Bahamian ... , Prime Minister Perry Christie said the government has completed ...
(Date:10/30/2014)...  Regado Biosciences, Inc. (Nasdaq: RGDO ), ... and live audio webcast on Thursday, November 6, 2014, ... 2014 financial results. Interested participants and investors ... for domestic callers or (412) 902-4276 for international callers. ... investor relations section of the Regado website at ...
(Date:10/27/2014)... Cary, North Carolina (PRWEB) October 27, 2014 ... was invited earlier this month to sit down with Bryan ... Spencer from RPG Solutions to discuss talent in the Research ... the topics that were highlighted at the roundtable ... in the Triangle, the significance of work/life balance and the ...
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
Breaking Biology Technology:Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
Cached News: